Although the search for a somatic HER2 oncogenic mutation in HER2-amplified breast tumours has failed to identify a promising activating genetic lesion [104–106], the existence of HER2 isoforms that may influence trastuzumab response in breast tumours evidenced the key role of AS in chemoresistance [107–109]. This evidence concerns the gene ERBB2 and breast neoplasm.